Skip to main content

Table 1 Laboratory Data

From: Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma

Variable (normal range)

1.5 months prior to admission

At the time of hospital admission

2.5 months following admission

Hematocrit (%) (35.7–46.7)

41

30.1

38.3

Hemoglobin (g/dl) (12.1–16.3)

13.2

9.8

12.3

White Cell Count (*109/L) (4–11.1)

6.9

7.5

8.4

Differential (%)

 Neutrophils

74.9

80.5

85.6

 Band forms

0

0.6

0.6

 Lymphocytes

13.7

6.7

7.0

 Monocytes

9.1

9.9

5.6

Mean Corpuscular volume (fL) (80–100)

91.1

87.5

97

Erythrocyte count (*1012/L) (4.18–5.64)

4.5

3.44

3.95

Potassium (mmol/L) (3.5–5.1)

4.4

4.1

4.5

Sodium (mmol/L) (133–145)

137

136

135

Chloride (mmol/L) (98–108)

103

107

103

Blood Urea Nitrogen (mg/dl) (7–25)

16

22

32

Creatinine (mg/dl) (0.6–1.2)

0.98

1.47

1.86

Calcium (mg/dl) (8.6–10.3)

9.2

8.6

9.2

Glucose (mg/dl) (70–199)

99

162

124

Alkaline Phosphatase (U/L) (39–117)

114

96

64

Alanine Aminotransferase (U/L) (7–52)

12

13

19

Aspartate Aminotransferase (U/L) (12–39)

30

17

19

Bilirubin total (mg/dl) (0.1–1.3)

0.7

0.6

0.7

Total protein (g/dl) (6.4–8.9)

7.1

6.6

6.4

Albumin (g/dl) (3.5–5.7)

3.6

2.9

3.8

ESR (mm/hr) (0–20)

 

75

12

Anti DNA Ab

 

Negative

 

Anti Centromere Ab

 

Negative

 

Anti RNP Ab

 

Negative

 

Anti Smith Ab

 

Negative

 

Anti SSA Ab

 

Negative

 

Anti SSB Ab

 

Negative

 

ANA

 

> 1:320, speckled

 

Anti MPO Ab (0–20 units)

 

> 30

> 30

C-ANCA

 

Negative

Negative

P-ANCA

 

1:640

1:80

C3 omplement (mg/dl) (87–200)

 

110

 

C4 Complement (mg/dl) (19–52)

 

25.1

Â